AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00582608
Drug: 8H9
RxNorm normalized name: 131-I-8H9 monoclonal antibody
DrugBank: Omburtamab I-131 (DB17124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 50mg/1.73m\^2 of unlabeled 8H9.
Trial: NCT00894608
Drug: letrozole + gonadotropins
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
Trial: NCT00894608
Drug: GnRHa + gonadotropins
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
Trial: NCT02423395
Drug: orphenadrine
RxNorm normalized name: Orphenadrine
DrugBank: Orphenadrine (DB01173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orphenadrine in muscle cramps in cirrhotic patients
Trial: NCT01539330
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po
Trial: NCT00089063
Drug: Montanide ISA 51 VG
RxNorm normalized name: Montanide ISA 51 VG
DrugBank: Incomplete Freund's adjuvant (DB17475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT00653458
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ODT, 8 mg, single-dose, fed conditions
Trial: NCT00647738
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 20 mg immediate-release oral tablets
Trial: NCT00647738
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 20 mg immediate-release oral tablet
Trial: NCT00653458
Drug: Zofran
RxNorm normalized name: Zofran
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ODT, 8 mg, single-dose, under fed conditions
Trial: NCT01180348
Drug: Botulift
RxNorm normalized name: Bosulif
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
Trial: NCT01180348
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
Trial: NCT00647465
Drug: vaccine
RxNorm normalized name: VACCINES
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNalpha 2b
Trial: NCT00006351
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006351
Drug: lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01416493
Drug: s.c. injections of bovine intestinal Alkaline Phosphatase
DrugBank: Alkaline Phosphatase (DB05768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily subcutaneous treatment with two injections of 2000IU bIAP for three days
Trial: NCT00226460
Drug: Fetal porcine cells, Neurocell-PD
DrugBank: NeuroCell-PD (DB17941)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01686126
Drug: Levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrauterine device
Trial: NCT01686126
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral medication
Trial: NCT02842580
Drug: acide folinique
RxNorm normalized name: Acide folinique
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m² if Elvorine
Trial: NCT00265135
Drug: CNTO 328
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
Trial: NCT00316810
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 0: Campath 30 mg i.v. infusion over 3-6 hours
Trial: NCT00316810
Drug: Rabbit Anti-Human Thymocyte Globulin
RxNorm normalized name: Rabbit anti-human thymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
Trial: NCT03062462
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days
Trial: NCT03062462
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
Trial: NCT01323530
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV) bolus or infusion.
Trial: NCT02842580
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.
Trial: NCT02842580
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.
Trial: NCT02842580
Drug: capécitabine
RxNorm normalized name: Capécitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Trial: NCT02842580
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
Trial: NCT00245089
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02367027
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
Trial: NCT02367027
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 20 mg oral suspension (dry powder) in fed conditions.
Trial: NCT02367027
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 10 mg oral suspension in fasted conditions.
Trial: NCT02367027
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 10 mg tablet in fasted conditions.
Trial: NCT03642964
Drug: CTC-501
RxNorm normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pramipexole IR, given with ondansetron
Trial: NCT01102257
Drug: Olive Oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
Trial: NCT02809079
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 500mg Bid
Trial: NCT02809079
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisone 10mg Qd
Trial: NCT00003446
Drug: trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02295046
Drug: Amlodipine besylate/Atorvastatin calcium
RxNorm normalized name: Amlodipine Besylate/Atorvastatin Calcium 5 MG-80 MG Oral Tablet
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate/Atorvastatin calcium 10/80 mg
Trial: NCT03324555
Drug: ORIC-101
RxNorm normalized name: Oriconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT02101736
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is an open label Phase II clinical trial. For both cohorts, subjects will receive cabozantinib orally in continuous cycles. Each cycle is 28 days. In absence of progressive disease or dose limiting toxicity (DLT), subjects may continue therapy for a total of 24 cycles. Subjects with radiographic response (20% or greater reduction in tumor volume) at the end of 12 cycles can continue on therapy for up to an additional year. However, for Cohort A, subjects who do not achieve 15% reduction in tumor volume after 8 cycles will be considered treatment failure and taken off study. For Cohort B, the criteria that subjects who do not achieve 15% reduction by 8 cycles are considered treatment failure and taken off study was eliminated. Subjects will be carefully monitored for toxicities associated with cabozantinib.
Trial: NCT02309762
Drug: FB825
RxNorm normalized name: FB825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
Trial: NCT00140244
Drug: r-metHuLeptin
RxNorm normalized name: r-metHuLeptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00424619
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 000 IU vitamin D2, one time bolus dose
Trial: NCT00424619
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 000 IU vitamin D2, one time bolus dose
Trial: NCT03581058
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
Trial: NCT01342770
Drug: Pioglitazone Hydrochloride
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00083759
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00869999
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taken orally once daily in the morning
Trial: NCT01530217
Drug: Ibuprofen.
DrugBank: Ibuprofen piconol (DB16887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
Trial: NCT00869999
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
Trial: NCT04400851
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were enrolled by the design of phase I study standard. Sintilimab was divided into three dosage levels: 1 mg / kg, 3 mg / kg, and 10 mg / kg. The first level of sintilimab was followed by dose escalation
Trial: NCT02347774
Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer
RxNorm normalized name: clozapine
DrugBank: SUN-101 (DB17238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CS) nebulizer
Trial: NCT02347774
Drug: SUN-101 25 mcg BID eFlow (CS) nebulizer
RxNorm normalized name: MyoGesic-CS
DrugBank: SUN-101 (DB17238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUN-101 25 mcg BID eFlow (R) Closed System (CS) nebulizer
Trial: NCT00921557
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
Trial: NCT02681848
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smoking cessation medication
Trial: NCT02681848
Drug: Nicotine replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00746746
Drug: Pegylated Interferon-Alpha 2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6.0 mcg/kg weekly
Trial: NCT04112043
Drug: Nicotinamide Riboside (NR)
RxNorm normalized name: nicotinamide ribotide
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this intervention will receive 1,000 mg/day of NR.
Trial: NCT00212342
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02464813
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
Trial: NCT02464813
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
Trial: NCT02464813
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
Trial: NCT04441528
Drug: Lid wipes containing terpinen-4-ol and sodium hyaluronate
RxNorm normalized name: .GAMMA.-TERPINENE
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
Trial: NCT01194570
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
Trial: NCT05393856
Drug: CG-549
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART A (open-label)~Period 1: single oral dose. Period 2: After PK evaluation of period 1. Period 3: After PK evaluation of period 2.~PART B (randomized)~* Period 1: a single oral dose of ZZ mg CG-549 on Day 1 in fed or fasted state.~* Period 2: a single oral dose of ZZ mg CG-549 on Day 1 in fasted or fed state.
Trial: NCT04414020
Drug: Progesteron
RxNorm normalized name: Progesteron
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intramusculer progesterone
Trial: NCT01557374
Drug: Tocilizumab, Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
Trial: NCT01557374
Drug: Decrease Tocilizumab, Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~* If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~* If DAS 28 \> 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~* If DAS 28 \> 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study.
Trial: NCT02189343
Drug: ACY-1215 in combination with pomalidomide and dexamethasone
RxNorm normalized name: Pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
Trial: NCT00109031
Drug: palifermin
RxNorm normalized name: palifermin
DrugBank: Palifermin (DB00039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as one daily intravenous bolus.
Trial: NCT00281788
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00281788
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02807727
Drug: Intralipid 20%
RxNorm normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
Trial: NCT02384746
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg intramuscular every 28 days
Trial: NCT00109031
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
Trial: NCT01822756
Drug: ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01822756
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Other names: Gemzar®
Trial: NCT01822756
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Other names: Abraxane®
Trial: NCT01822756
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
Trial: NCT00336349
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum Toxin Type A
Trial: NCT01834885
Drug: fluticasone/salmeterol
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fluticasone/slameterol via inhaler twice a day
Trial: NCT00003140
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01155440
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% Lidocaine 1mg/kg/hr IV drip x 48hr
Trial: NCT02729766
Drug: Empagliflozin 25mg Tbl
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes